Predictive Value of Serum VEGF Levels in Non-Small Cell Lung Cancer: A Review
Oncology Research · 2025
DOI: 10.32604/or.2025.066228 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Research, 2025. Verfasst von Eleni Kokkotou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, Third Department of Medicine, "Sotiria" General Hospital for Chest Diseases, National and Kapodistrian University of Athens, Athens, 1…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Vascular Endothelial Growth Factor A, Biomarkers, Tumor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) serve an essential role in tumor angiogenesis and have emerged as potential therapeutic targets in lung cancer. This review explores the significance of serum VEGF levels as a predictive biomarker in non-small cell lung cancer (NSCLC). The VEGF family, consisting of VEGFA, VEGFB, VEGFC, VEGFD, and placenta growth factor (PlGF), engages with specific receptors, including tyrosine kinase receptors (VEGFR-1, VEGFR-2, and VEGFR-3) and neuropilin receptors (NRP-1 and NRP-2), to promote angiogenesis and lymphangiogenesis. VEGF-A, the primary component of the VEGF family, binds to VEGFR-2 to stimulate endothelial cell proliferation and migration, while VEGF-B, VEGF-C, and VEGF-D interact with VEGFR-1 and VEGFR-3 to regulate tumor angiogenesis, lymphangiogenesis, and metastasis. The VEGF/VEGFR signaling pathway activates various downstream effectors, including phospholipase Cγ1, mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt), which are essential for maintaining vascular homeostasis and promoting angiogenesis. In NSCLC, elevated serum VEGF levels have been observed, and the VEGF/VEGFR axis is frequently impaired, leading to irregular blood vessel formation and metastatic spread. Despite the development of anti-VEGF therapies, their impact on lung cancer outcomes has been limited. Further research is needed to optimize the effectiveness of these treatments and elucidate the potential of serum VEGF as a predictive biomarker in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Unit, Third Department of Medicine, "Sotiria" General Hospital for Chest Diseases, National and Kapodistrian University of Athens, Athens, 11527, Greece.
Zitieren
APA
Kokkotou, E., Charpidou, A., & Syrigos, N. (2025). Predictive Value of Serum VEGF Levels in Non-Small Cell Lung Cancer: A Review. Oncology Research. https://doi.org/10.32604/or.2025.066228
Vancouver
Kokkotou E, Charpidou A, Syrigos N. Predictive Value of Serum VEGF Levels in Non-Small Cell Lung Cancer: A Review. Oncology Research. 2025. doi:10.32604/or.2025.066228
BibTeX
@article{Kokkotou2025,
author = {Kokkotou, Eleni and Charpidou, Andriani and Syrigos, Nikolaos},
title = {Predictive Value of Serum VEGF Levels in Non-Small Cell Lung Cancer: A Review},
journal = {Oncology Research},
year = {2025},
doi = {10.32604/or.2025.066228}
}
EUVIMED